stars 1 stars 2 stars 3

SuriCog was founded in mid-2013 by Marc Massonneau, serial entrepreneur in medical devices & services, and some other passionate people, to develop new generation of gaze-based diagnostic tools in order to improve patient pathways in neurology and psychiatry. In 2016, we acquired a company which developed a 10M€ program for best-in-class eye-movement acquisition and analysis solutions in several key neurological diseases Drawing from over a quasi-decade of eye studies, algorithm development, optoelectronics design, high-end software, and clinical trials and applications, we have advanced our technology for integration in a data-driven complete solution, as the fundamental for medical oriented eye-tracking. The aim is to approach the most complex organ, the brain, with the right tools for a simple and efficient integration of advanced research into daily medical practice. SuriCog now has more than 20 issued and pending patents, nearly 100 scientific publications with results in ten neuro-diseases and is present in more than 10 countries. And all developments are carried out in strict accordance with medical regulations. The SuriCog team has over 90 years of combined experience in medical device, drug development, clinical trials, market access, engineering, sales operations, and, moreover, imbued with in-depth neuroscientific expertise and medical empathy.

Suricog Questions

The Suricog annual revenue was $4 million in 2026.

Jean Cuiné is the CEO of Suricog.

15 people are employed at Suricog.

Suricog is based in Paris, Ile-de-France.

The NAICS codes for Suricog are [541713, 54171, 541, 5417, 54].

The SIC codes for Suricog are [873, 87].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users